Oncology & Cancer

Pazopanib shows better quality-of-life in advanced kidney cancer

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...

Oncology & Cancer

FDA approved drug extends survival for patients with rare cancer

Sunitinib, an agent approved for use in several cancers, provides unprecedented antitumor activity in thymic carcinoma, a rare but aggressive tumor of the thymus gland, according to a phase II clinical trial led by a researcher ...

Oncology & Cancer

Nivolumab plus ipilimumab tops sunitinib for advanced renal CA

(HealthDay)—For patients with previously untreated clear-cell advanced renal-cell carcinoma, nivolumab plus ipilimumab is associated with better overall survival than sunitinib, according to a study published online March ...

Oncology & Cancer

Atezolizumab + bevacizumab shows benefit in met renal CA

(HealthDay)—For patients with metastatic renal cell carcinoma (mRCC), atezolizumab plus bevacizumab is associated with a progression-free survival benefit versus sunitinib, according to a study presented at the American ...

page 1 from 2